Clinical Trial
Study Details
Enrollment
15
Interventions
Description
Intravenous GMI-1070 given as two doses over the course of one day
Name
GMI-1070
Type
Drug
Phase
Phase 1
Phase 2
Status
COMPLETED
Study ID #
NCT00911495
Study Type
Interventional
Summary
This Phase 1/Phase 2 study will evaluate GMI-1070, a pan-selectin inhibitor, in adults with stable sickle cell disease. The study will assess safety, pharmacokinetics, and microvascular effects of intravenous GMI-1070 in the outpatient setting.
Study Overview
Conditions
Contacts and Locations
Locations
Facility
Children's Hospital & Research Center Oakland
Oakland, California 94609
United States
GeoPoint
37.80437, -122.2708
Facility
University of California at Davis, CCRC
Sacramento, California 95817
United States
GeoPoint
38.58157, -121.4944
Facility
Duke Comprehensive Sickle Cell Center
Durham, North Carolina 27710
United States
GeoPoint
35.99403, -78.89862